Global Vaccine Market Pipeline Analysis

Publish Date:- Jan-2014       No Of Pages (1550)

Electronic Access - Single User License $1500 Buy Now
CD-ROM Mail Delivery $1800Buy Now
Hard Copy Mail Delivery $2000 Buy Now
Electronic Access - Multi-User License $2200 Buy Now


The global vaccine market is characterized into human and animal vaccines. The segment of human vaccines is further sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the global pharmaceutical drug sales(2-3%), the growth rate in this market has been extraordinary. This segment has grown at a high rate of 10-15% annually as compared to the overall pharmaceutical industry which grows at 5-7% per year.

The global market for vaccines is currently estimated to be worth more than US$ 30 Billion. with factors like advances in immunology, genetics and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass estimated USD 100 billion by 2025.

Global Vaccine Market Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various vaccines being developed across multiple indications. Research report covers all vaccines being developed in various clinical phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the global vaccines market based upon development process.

Following parameters for each drug profile in development phase are covered in “Global Vaccine Market Pipeline Analysis” research report:

• Drug Profile Overview

• Active Indication

• Phase of Development

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• Patent Information

• Molecular Formula

• Brand Names

• Development Agreements

• ATC Codes



Number of Vaccines in Pipeline by Clinical Phase:

• Research: 110

• Preclinical: 378

• Clinical: 15

• Phase 0: 1

• Phase-I: 177

• Phase-I/II: 69

• Phase-II: 137

• Phase-II/III: 11

• Phase-III: 52

• Preregistration: 15

• Registered: 20

• Marketed: 156

• Unknown: 1


The global vaccine market is characterized into human and animal vaccines. The segment of human vaccines is further sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the global pharmaceutical drug sales(2-3%), the growth rate in this market has been extraordinary. This segment has grown at a high rate of 10-15% annually as compared to the overall pharmaceutical industry which grows at 5-7% per year.

The global market for vaccines is currently estimated to be worth more than US$ 30 Billion. with factors like advances in immunology, genetics and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass estimated USD 100 billion by 2025.

Global Vaccine Market Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various vaccines being developed across multiple indications. Research report covers all vaccines being developed in various clinical phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the global vaccines market based upon development process.

Following parameters for each drug profile in development phase are covered in “Global Vaccine Market Pipeline Analysis” research report:

• Drug Profile Overview

• Active Indication

• Phase of Development

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• Patent Information

• Molecular Formula

• Brand Names

• Development Agreements

• ATC Codes



Number of Vaccines in Pipeline by Clinical Phase:

• Research: 110

• Preclinical: 378

• Clinical: 15

• Phase 0: 1

• Phase-I: 177

• Phase-I/II: 69

• Phase-II: 137

• Phase-II/III: 11

• Phase-III: 52

• Preregistration: 15

• Registered: 20

• Marketed: 156

• Unknown: 1

1. Global Vaccine Market Overview



2. Vaccine Clinical Development Phase: Unknown

  2.1 Overview

  2.2 Vaccine Profile in Clinical Phase



3. Vaccine Clinical Development Phase: Research

  3.1 Overview

  3.2 Vaccine Profile in Clinical Phase



4. Vaccine Clinical Development Phase: Preclinical

  4.1 Overview

  4.2 Vaccine Profile in Clinical Phase



5. Vaccine Clinical Development Phase: Clinical

  5.1 Overview

  5.2 Vaccine Profile in Clinical Phase



6. Vaccine Clinical Development Phase: Phase-0

  6.1 Overview

  6.2 Vaccine Profile in Clinical Phase



7. Vaccine Clinical Development Phase: Phase-I

  7.1 Overview

  7.2 Vaccine Profile in Clinical Phase



8. Vaccine Clinical Development Phase: Phase-I/II

  8.1 Overview

  8.2 Vaccine Profile in Clinical Phase



9. Vaccine Clinical Development Phase: Phase-II

  9.1 Overview

  9.2 Vaccine Profile in Clinical Phase



10. Vaccine Clinical Development Phase: Phase-II/III

  10.1 Overview

  10.2 Vaccine Profile in Clinical Phase



11. Vaccine Clinical Development Phase: Phase-III

  11.1 Overview

  11.2 Vaccine Profile in Clinical Phase



12. Vaccine Clinical Development Phase: Preregistration

  12.1 Overview

  12.2 Vaccine Profile in Clinical Phase



13. Vaccine Clinical Development Phase: Registered

  13.1 Overview

  13.2 Vaccine Profile in Clinical Phase



14. Marketed

  14.1 Overview

  14.2 Vaccine Profile in Market


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name